METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

1 . A method for evaluating renal status in a subject, comprising:

performing one or more assays configured to detect one or more biomarkers selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 by introducing a body fluid sample obtained from the subject into an assay instrument which (i) for each analyte binding assay performed, contacts all or a portion of the urine sample with a binding reagent which specifically binds for detection the kidney injury marker which is assayed, and (ii) generates one or more assay results indicative of binding of each biomarker which is assayed to its respective binding reagent;

correlating the assay result(s) to the renal status of the subject, wherein said correlation step comprises correlating the assay result(s) to one or more of diagnosis, risk stratification, prognosis, classifying and monitoring of the renal status of the subject by using the assay result(s) to assign the patient to a predetermined subpopulation of individuals having a known predisposition of a current or future acute renal injury; and

treating the patient based on the predetermined subpopulation of individuals to which the patient is assigned, wherein the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.

2 . A method according to claim 1 , wherein said correlation step comprises correlating the assay result(s) to prognosis of the renal status of the subject.

3 . A method according to claim 1 , wherein said correlating step comprises assigning a likelihood of one or more future changes in renal status to the subject based on the assay result(s).

4 . (canceled)

5 . A method according to claim 1 , wherein said assay results comprise at least 2, 3, or 4 of:

a measured concentration of Growth/differentiation factor 2, a measured concentration of Catalase, a measured concentration of Vascular endothelial growth factor C, and a measured concentration of Melanoma-derived growth regulatory protein.

6 . A method according to claim 1 , wherein a plurality of assay results are combined using a function that converts the plurality of assay results into a single composite result.

7 . A method according to claim 3 , wherein said one or more future changes in renal status comprise a clinical outcome related to a renal injury suffered by the subject.

8 . A method according to claim 3 , wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within 30 days of the time at which the body fluid sample is obtained from the subject.

9 . A method according to claim 8 , wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 18 hours, and 12 hours.

10 . A method according to claim 1 , wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

11 . A method according to claim 1 , wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

12 . A method according to claim 1 , wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result(s).

13 . A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of an injury to renal function in said subject.

14 . A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of reduced renal function in said subject.

15 . A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for dialysis in said subject.

16 . A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of acute renal failure in said subject.

17 . A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal replacement therapy in said subject.

18 . A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal transplantation in said subject.

19 - 21 . (canceled)

22 . A method according to claim 1 , wherein the subject is in RIFLE stage 0 or R.

23 - 49 . (canceled)

50 . A method according to claim 1 , wherein the subject is not in acute renal failure.

51 - 121 . (canceled)